Bioanalytical Method Development & Validation of a Trapping-Nano-Hybrid LBA/LCMS method for Clinical Studies

Recent Application of Highly Sensitive Methods for Quantitation of Biotherapeutics in Regulated Bioanalysis

In partnership with Glenmark Pharmaceuticals, this presentation highlights Nano-LC-MS considerations, such as sensitivity, robustness, speed, ease of use, and LC system volumes. It also features our platform for protein therapeutic quantitation by LC-MS, as well as a case study of Glenmark's GBR 1302, a HER2xCD3 bispecific antibody and the first clinical candidate based on Glenmark’s proprietary BEAT® platform. 

Download the presentation to learn more.